Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1-Infected, Treatment-Experienced Patients

BACKGROUND: Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity. METHODS: Phase 2, double-blind, randomized study of vicriviroc in treatment-experienced subjects with CCR5-using HIV-1. Vicriviroc (5, 10 or 15 mg) or placebo was added to a failin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wilkin, Timothy J., Su, Zhaohui, Krambrink, Amy, Long, Jianmin, Greaves, Wayne, Gross, Robert, Hughes, Michael D., Flexner, Charles, Skolnik, Paul R., Coakley, Eoin, Godfrey, Catherine, Hirsch, Martin, Kuritzkes, Daniel R., Gulick, Roy M.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917795/
https://ncbi.nlm.nih.gov/pubmed/20672447
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars